Some important issues in the planning of phase III HIV vaccine efficacy trials

Vaccine

Volumn 17, Issue 7-8, 1999, Pages 989-1004

  Boily, M C ^a   Masse B R ^a   Desai, K ^a   Alary, M ^a   Anderson, R M ^b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

AIDS; Clinical trials; Efficacy measures; HIV; Mathematical models; Sample size; Trial simulations; Vaccine

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ARTICLE; CALCULATION; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PLASMID; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SAMPLE; STATISTICAL ANALYSIS; SUPPRESSOR CELL; VACCINATION;

AIDS VACCINES; CLINICAL TRIALS, PHASE III; HUMANS; RANDOMIZED CONTROLLED TRIALS;

EID: 0345471386     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00316-8     Document Type: Article

References (113)

1. Balter M. First AIDS vaccine launched. Science. 280:1998;1697.
2. Ada G., Blanden B., Mullbacher A. HIV: to vaccinate or not to vaccinate? Nature. 359:1992;572.
3. Burke D.S. International vaccine efficacy trials: special considerations. AIDS Research and Human Retroviruses. 8:1992;1531.
4. Petricciani J.C., Koff W.C., Ada G.L. Efficacy trials for HIV/AIDS vaccines. AIDS Research and Human Retroviruses. 8:1992;1527-1529.
5. Harting S., Norley S.G. Vaccine protection against SIVmac infection by high- but not low-dose whole inactivated virus immunogen. J Acquir Immune Defic Syndr. 5:1992;461-468.
6. Johnson P.R., Montefiore D.C., Goldstein S., et al. Inactivated whole-virus vaccine derived from a proviral DNA clone of Simian immunodeficiency virus induces high levels of neutralizing antibodies and confers protection against heterologous challenge. Proc Natl Acad Sci. 9:1992;2175-2179.
7. Stahl-Hennig C., Voss G., Nick S., et al. Immunization with Tween-ether-treated STV absorbed onto aluminum hydroxide protects monkeys against experimental SIV infection. Virology. 186:1992;588-596.
8. Langlois A.J., Weinhold K.J., Matthews T.J., et al. The ability of certain SIV vaccines to provoke reactions against normal cells. Science. 255:1992;292-293.
9. Schaper C., Fleming T.R., Self S.G., Rida W.N. Statistical issues in the design of HIV vaccine trials. Annu Rev Public Health. 16:1995;1-22.
10. Grady C. HIV preventive vaccine research: selected ethical issues. J Med Philos. 19:(6):1994;595-612.
11. Dixon D.O., Rida W.N., Fast P.E., Hoth D.F. HIV vaccine trials: some design issues including sample size calculation. J Acquir Immune Defic Syndr. 6:1993;485-496.
12. Lallemant M., Le Coeur S. Expérimentation clinique des vaccins contre le VIH: Dilemmes scientifiques et éthiques. Hist Phil Life Sci. 17:1995;151-169.
13. Hoff R., Barker L.F. Trial objectives and end points for measuring the efficacy of HIV vaccines. Infect Agents Dis. 4:(2):1995;95-101.
14. Lurie P., et al. Ethical, behavioral, and social aspects of HIV vaccine trials in developing countries. JAMA. 271:(4):1994;295-301.
15. Katongole-Mbidde E. Expectations of host countries in HIV vaccine trials. AIDS Research and Human Retroviruses. 9:1993;S17-S19.
16. Bloom B.R. The highest attainable standard: ethical issues in AIDS vaccines. Science. 279:1998;186-188.
17. Karzon D.T., Bolognesi-Dp, Koff W.C. Development of a vaccine for the prevention of AIDS, a critical appraisal. Vaccine. 10:(14):1992;52-1039.
18. Girard M. The needs and hopes for an AIDS vaccine. Biochimie. 75:1993;583-589.
19. Nowak M.A., McLean A.R. A mathematical model of vaccination against HIV to prevent the development of AIDS. Proc R Soc Lond. 246:1991;141-146.
20. Summary report recommendations of an international ad hoc cientific committee. HIV vaccines: accelerating the development of preventive HIV vaccines for the world. October 27-28, 1994, Le Val de Grace, Paris, France, 1995.
21. Haynes B.F. HIV vaccines: where we are and where we are going. Lancet. 348:1996;933-937.
22. Grady C., Kelly G. State of the science: HIV vaccine development. Nurs Clin North Amer. 31:(1):1996;25-39.
23. Esparza J., Heyward W.L., Osmonov S. HIV vaccine development: from basic research to human trials. AIDS. 10:(Suppl A):1996;S123-S132.
24. Kahn J.O., Birx D.L. Vaccines directed against HIV: preventive and therapeutic strategies. AIDS Clin Rev. 94:1993;213-238.
25. Ugen K.E., et al. Nucleic acid immunization of chimpanzees as a prophylactic/immunotherapeutic vaccination model for HIV-1: prelude to a clinical trial. Vaccine. 15:(8):1997;927-930.
26. Shiver J.W., et al. Anti-HIV env immunities elicited by nucleic acid vaccines. Vaccine. 15:(8):1997;884-887.
27. Fuller, et al. Enhancement of immunodeficiency virus-specific immune responses in DNA-immunized rhesus macaques. Vaccine. 15:(8):1997;924-926.
28. Barnett S.W., et al. Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by recombinant gp-120 protein subunit. Vaccine. 15:(8):1997;869-873.
29. Haynes B.F., Putnam S.B., Weinberg J.B. Update on the issues of HIV vaccine development. Ann Med. 28:1996;39-41.
30. AIDS Vaccine Evaluation Group (AVEG) http://camelot.emmes.com/avctn/index.htm.
31. Cohen J. Planned tests in Thailand spark debate. Science. 276:1997;1197.
32. Bryson Y.J., Pang S., Wei L.S., Dickover R., Diagne A., Chen I.S.Y. Clearance of HIV infection in a perinatally infected infant. New Engl J Med. 332:1995;833-838.
33. Panteleo G., Menzi S., Vaccarezza M., et al. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. New Engl J Med. 332:1995;209-216.
34. Cao Y., Qin L., Zhang L., Safrit J., Ho D.D. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. New Engl J Med. 332:1995;201-208.
35. Rowland-Jones S., Sutton J., Ariyoshi K., et al. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nature Med. 1:1995;59-64.
36. Fowke K.R., Nagelkerke N., Kimani J., et al. Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya. Lancet. 348:1996;1347-1351.
37. Samson M., Libert F., Doranz B., et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature. 382:1996;722-725.
38. Daniel M.D., Kirchhoff F., Czajak S.C., et al. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science. 258:1992;1938-1941.
39. Rowe P.M. Two candidates for a live AIDS vaccine emerge. Lancet. 348:1996;742.
40. Powell M.F. Drug delivery issues in vaccine development. Pharmaceutical Research. 13:(12):1996;1777-1785.
41. NIAID Division of AIDS. HIV Vaccine Working Group, April 21-22, 1994 Meeting.
42. Johnston M., Fast P., Schultz A., Hoth D. Progress toward development of a vaccine to prevent AIDS. AIDS Research and Human Retroviruses. 9:(Suppl 1):1993;S117-S122.
43. Esparza J., Osmanov S., Kallings L.O., Wigzell H. Planning for HIV vaccine trials. The World Health Organization Perspective. AIDS. 5:(Suppl 2):1992;S159-S163.
44. Nelson K.E., Beyrer C., Natpatan C., Eiumtrakul S., Celentano D.D., Khamboonruang C. Preparatory studies for possible HIV vaccine trials in northern Thailand. AIDS Research and Human Retroviruses. 10:(Suppl 2):1994;S243-S246.
45. Weniger B.G. Experience from HIV incidence cohorts in Thailand: implications for HIV vaccine efficacy trials. AIDS. 8:1994;1007-1010.
46. Celentano D.D., Beyrer C., Natpratan C., et al. Willingness to participate in AIDS vaccine trials among high-risk populations in northern Thailand. AIDS. 9:1995;1079-1083.
47. Kanai K., Kurata T. Review: collected materials and records of HIV/AIDS prevalence and the contemporary social changes in Thailand. Jpn Med Sci Biol. 48:1995;1-48.
48. Heyward W.L., Osmonov S., Esparza J. Establishment of WHO-sponsored field sites for HIV vaccine evaluation in developing countries. Antibiot Chemother. 48:1996;139-144.
49. Heyward W.L., Osmanov S., Saba J., et al. Preparation for Phase III HIV vaccine efficacy trials: methods for the determination of HIV incidence. AIDS. 8:1994;1285-1291.
50. Auerbach J.D. The role of behavioral research in HIV/AIDS prevention. Current Opinion in Infectious Diseases. 11:1998;3-7.
51. Cohen J. Looking for leads in HIV's battle with immune system. Science. 276:1997;1196-1197.
52. AIDS Vaccine Advocacy Coalition. 1998. Moving toward efficacy studies, http://www.vaccineadvocates.org/avacsite/ battling.html.
53. Korzun AH, Chaloner K. Protocol Development. AIDS Clinical Trials, Chapter 5. New York: Wiley-Liss, 1995.
54. Rida W.N., Lawrence D.N. Some statistical issues in HIV vaccine trials. Statistics in Medicine. 13:1994;2155-2177.
55. Rida WN, Lawrence DN. Prophylactic HIV vaccine trials. Chapter 21 in AIDS Clinical Trials. New York: Wiley-Liss, 1995.
56. Halloran M.E., Longini I.M. Jr, Haber M.J., Struchiner C.J., Brunet R.C. Exposure efficacy and change in contact rates in evaluating prophylactic HIV vaccines in the field. Statistics in Medicine. 13:(4):1994;77-357.
57. Struchiner C.J., Halloran M.E., Robins J.M., Spielman A. The behaviour of common measures of association used to assess a vaccination programme under complex disease transmission patterns - a computer simulation study of malaria vaccines. Int J Epidemiol. 19:1990;187-196.
58. Vaupel J.W., Manton K.G., Stallard E. The impact of heterogeneity in individual frailty on the dynamics of mortality. Demography. 16:(3):1979;439-454.
59. Vaupel J.W., Yashin A.I. Heterogeneity's ruses: some surprising effects on selection on population dynamics. The American Statistician. 39:(3):1985;176-185.
60. Halloran M.E., Struchiner C.J. Study designs for dependent happenings. Epidemiology. 2:1991;331-338.
61. Anderson R.M., May R.M. Immunisation and herd immunity. Lancet. 335:1990;641-646.
62. Greenland S., Frerichs R.R. On measures and models for the effectiveness of vaccines and vaccination programmes. Int J Epidemiol. 17:1988;456-463.
63. Boily M-C., Anderson R.M. Sexual contact patterns between men and women and the spread of HIV-1 in urban centres in Africa. IMA Journal of Mathematics Applied in Medicine and Biology. 8:1991;221-247.
64. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic research - principles and quantitative methods. Van Nostrand Reinhold, New York, 1982.
65. Collett D. Modelling Survival Data in Medical Research. Chapman and Hall, London, U.K, 1999.
66. Lachin J.M., Foulkes M.A. Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. Biometrics. 42:1986;507-519.
67. Koopman J.S., Longini I.M., Jacquez J.A., et al. Assessing risk factors for transmission of infection. Am J Epidemiol. 133:1991;1199-1209.
68. Anderson R.M., Garnett G.P. Low-efficacy HIV vaccines: potential for community-based intervention programmes. Lancet. 348:1996;13-1010.
69. May R.M., Anderson R.M. Spatial heterogeneity and the design of immunization programs. Mathematical Biosciences. 72:1984;83-111.
70. Anderson R.M., Crombie J.A., Grenfell B.T. The epidemiology of mumps in the UK: a preliminary study of virus transmission, herd immunity and the potential impact of immunization. Epidem Inf. 99:1987;65-84.
71. Anderson R.M., Grenfell B.T. Quantitative investigations of different vaccination policies for the control of congenital rubella syndrome (CRS) in the United Kingdom. J Hyg Camb. 96:1986;305-333.
72. Mclean A., Blower S.M. Imperfect vaccines and herd immunity to HIV. Proc R Soc Lond B. 293:1993;9-13.
73. Smith P.G., Rodrigues L.C., Fine P.E.M. Assessment of the protective efficacy of vaccines against common diseases using case-control and cohort studies. Int J Epidemiol. 13:1984;87-93.
74. Halloran M.E., Haber M., Longini I.M. Interpretation and estimation of vaccine efficacy under heterogeneity. Am J Epidemiol. 136:1992;328-343.
75. Koopman J.S., Longini I.M., Jacquez J.A., et al. Assessing risk factors for transmission of infection. Am J Epidemiol. 133:1991;1199-1209.
76. Estimation of vaccine efficacy in outbreaks of acute infectious disease. Stat Med. 10:1991;1573-1584.
77. Haber M., Longini I.M., Halloran M.E. Measures of the effects of vaccination in a randomly mixing population. Int J Epidemiol. 20:1991;300-310.
78. Haber M., Halloran E.M., Longini I.M., Watelet L. Estimation of vaccine efficacy in non-randomly mixing populations. Biom J. 37:1995;25-38.
79. Haber M., Watelet L., Halloran E. On individual and population effectiveness of vaccination. Int J of Epidemiology. 24:(6):1995;1249-1260.
80. Halloran E.M., Longini I.M., Struchiner C.J. Estimability and interpretation of vaccine efficacy using frailty mixing models. Am J Epidemiology. 144:(1):1996;83-97.
81. Longini I.M., Datta S., Halloran M.E. Measuring vaccine efficacy for both susceptibilty to infection and reduction in infectiousness for prophylactic HIV-1 vaccines. J AIDS and Human Retrovirology. 13:1996;440-447.
82. Svenssen A. Analyzing effects of vaccines. Mathematical Biosciences. 107:1991;407-412.
83. Desai K, Boily M-C, Mâsse BR, Alary M, Anderson RM. How do we detect the true vaccinal efficacy in phase 3 HIV vaccine trials?. In: Abstract P763. 12th Meeting of the International Society of Sexually Transmitted Diseases Research. Seville (Spain), October 19-22, 1997, 1998.
84. Desai K, Boily M-C, Mâsse BR, Alary M, Anderson RM. Simulation studies of phase III clinical trial to test the efficacy of a candidate HIV-1 vaccine. (submitted), 1998.
85. Cohen J. Thailand weighs AIDS vaccine tests. Science. 270:1995;904-907.
86. Alonso P.L., Smith T., Schellenberg J.R., Masanja H., Mwankusye S., Urassa H., Bastos de Azevedo I., Chongela J., Kobero S., Menendez C., et al. Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania. Lancet. 344:1994;1175-1181.
87. Lachin J.M. Introduction to sample size determination and power analysis for clinical trials. Controlled Clinical Trials. 2:1981;93-113.
88. Koopman J.S., Little R.J. Assessing HIV vaccine effects. American Journal of Epidemiology. 142:(10):1995;1113-1120.
89. Cook J.A., Lawless J.F. Two-sample tests with multinomial or grouped failure time data. Biometrics. 47:1991;59-445.
90. Gentleman R., Geyer C.J. Maximum likelihood for interval censored data: consistency and computation. Biometrika. 81:(3):1994;23-618.
91. Freedman L.S. Tables of the number of patients required in clinical trials using the logrank test. Stat Med. 1:1982;121-129.
92. Lee ET. Statistical methods for survival data analysis, 2nd ed. John Wiley and Sons, 1992. p. 482.
93. Garnett G.P., Anderson R.M. Strategies limiting the spread of HIV in developing countries: conclusions based on studies of the transmission dynamics of the virus. J Acquired immune deficiency syndromes and human retrovirology. 9:1995;500-513.
94. Mastro T.D., Satten G.A., Nopkesorn T., et al. Probability of female-to-male transmission of HIV-1 in Thailand. Lancet. 343:1994;204-207.
95. Boily M-C. Transmission dynamics of coexisting chlamydial and HIV infections in the United States. In: Eng TR, Butler WT, editors. The Hidden Epidemic - Confronting Sexually Transmitted Diseases. Washington DC: National Academy Press, 1997. p. 316-329.
96. Boily M-C., Anderson R.M. HIV transmission and the role of other sexually transmitted diseases: measure of association. Sexually Transmitted Diseases. 23:(4):1996;312-332.
97. Kaplan E.H. Modeling HIV infectivity: Must sex act be counted? J Acquired Imm Def Synd. 3:1990;55-61.
98. Anderson R.M., Gupta S., Ng W. The significance of sexual partner contact networks for the transmission dynamics of HIV. J Acquir Immune Defic Syndr. 3:1990;417-419.
99. Mastro T.D., Limpakarnjanarat K. Condom use in Thailand: how much is it slowing the HIV/AIDS epidemic? AIDS. 9:1995;523-525.
100. Chuang C-Y., Chang P-Y., Lin K-C. AIDS in the Republic of China. Clinical Infectious Diseases. 17:(Suppl 2):1993;S40-S337.
101. Anderson R.M., May R.M. Infectious Diseases of Humans: Dynamics and Control. Oxford University Press, Oxford, 1991. p. 257.
102. Halpern J., Brown B.W. Jr. Designing clinical trials with arbitrary specification of survival functions and for the logrank or generalized Wilcoxon test. Controlled Clin Trials. 8:1987;177-189.
103. Halpern J., Brown B.W. Jr. A computer program for designing clinical trials with arbitrary survival curves and group sequential testing. Controlled Clin Trials. 14:1993;109-122.
104. Lakatos E. Sample sizes for clinical trials with time-dependent rates of losses and noncompliance. Controlled Clin Trials. 7:1986;189-199.
105. Lakatos E. Sample sizes based on the log-rank statistic in complex clinical trials. Biometrics. 44:1988;229-241.
106. Williams P.L. Sample size calculation for failure time data. In: Chapter 10 in AIDS Clinical Trials. New York: Wiley-Liss, 1995.
107. Brunet R.C., Struchiner C.J., Halloran M.E. On the distribution of vaccine protection under heterogeneous response. Mathematical Biosciences. 116:(1):1993;25-111.
108. VaxGen Website. 1998. http://www.vaxgen.com/vaccine.htm.
109. Esparza J., Osmanov S. The development and evaluation of HIV vaccines. Current Opinion in Infectious Diseases. 6:1993;218-229.
110. Cohen J. Jitters jeopardize AIDS vaccine trials. Science. 262:1993;980-981.
111. Osborn J.E. The rocky road to an AIDS vaccine. J Acquired Immune Deficiency Syndromes and Human Retrovirology. 9:1995;26-29.
112. Burton D.R., Moore J.P. Why do we not have an HIV vaccine and how can we make one? Nature Medicine. 4:(Suppl 5):1998;495.
113. Moore J., Anderson R. The WHO and why of HIV vaccine trials. Nature. 372:1994;313-314.